Single-dose Pharmacokinetics of Pociredir in Participants With Sickle Cell Disease

Part of paid clinical trials in Miami, Florida.

Sponsor
Fulcrum Therapeutics
Study ID
NCT07431398
Phase
PHASE1
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • Pociredir — DRUG
    Pociredir tablet formulation

Study Details

This clinical trial is a study to evaluate the pharmacokinetics of the tablet formulation Pociredir in fasted and fed state participants with Sickle Cell Disease (SCD).

Key Dates

First listed
Feb 24, 2026
Start date
Dec 13, 2025
Status verified
Jun 2026
Primary completion
Jun 1, 2026
Completion
Jun 1, 2026

Study Design

Enrollment
13 participants (actual)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Fasted Cohort
    Pociredir single dose tablet formulation under fasted conditions.
  • Experimental: Fed Cohort
    Pociredir single dose tablet formulation under fed conditions (after a high-fat breakfast).

Primary Outcome Measure

Plasma concentration of pociredir under fasted and fed conditions [ Time Frame: Day 1 through Day 4 ]

Locations (6)

FacilityCityStateZIPSite coordinators
Advanced Pharma - MiamiMiamiFlorida33147-
Omega Research GroupOrlandoFlorida32808-
Sonar Clinical ResearchRiverdaleGeorgia30274-
Neuro-Behavioral Clinical ResearchNorth CantonOhio44720-
University of Texas Health Science Center HoustonHoustonTexas77030-
Worldwide Clinical TrialsSan AntonioTexas78217-

Find similar trials in Miami, FL

Nationwide
Sickle cell disease trials
By condition
Sickle cell disease
By research site
Advanced Pharma - Miami· Miami, FLOmega Research Group· Orlando, FLSonar Clinical Research· Riverdale, GANeuro-Behavioral Clinical Research· North Canton, OHUniversity of Texas Health Science Center Houston· Houston, TXWorldwide Clinical Trials· San Antonio, TX

Related Studies